IOVA
NASDAQ
$5.02
Iovance Biotherapeutics Inc (IOVA)
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $8.80 (+75.30%)
Market Cap
$2.08B
Free Cash Flow Yield
-14.69%
Beta (5Y)
1.59
Price Chart
Valuation
Market Cap$2.08B
P/S6.14
P/B2.43
Profitability
Total Revenue (TTM)$286M
Gross Profit (TTM)$113M
EBITDA-$350M
Profit Margin-123.9%
Operating Margin-113.5%
EPS-$0.92
Financial Health
Free Cash Flow Yield-14.69%
Growth & Risk
EPS 5Y CAGR-12.60%
FCF 5Y CAGR+3.32%
Beta (5Y)1.59
Sharpe Ratio1.20